藥明生物(02269.HK)擬向Bayer購買生物藥原液製造工廠設施資產
格隆匯 12 月 21日丨藥明生物(02269.HK)公告,公司間接全資附屬公司WuXi Biologics Germany與Bayer於2020年12月21日訂立資產購買協議,據此,Wu Xi Biologics Germany將向Bayer購買位於德國伍珀塔爾的生物藥原液製造工廠的設施資產,以持續擴大集團的全球產能,進一步滿足世界各地客户對生物藥生產不斷增長的需求。
為確保收購後製造工廠營運順暢,Wu Xi Biologics Germany將於完成日期與Bayer分別就製造工廠房屋的長期分租及若干相關過渡服務訂立分租協議及過渡服務合同。交易總值金額約為1.5億歐元。
董事認為,與集團自先前交易收購的位於德國利華古遜的生物藥製劑廠強強聯合,該等配有3條1000升灌流和6條2000升流加生產線的生物藥原液製造工廠將助力集團提供一流生物藥商業化產能,以滿足客户對生物藥外包服務日益增長的需求,同時進一步擴大其全球網絡,強化新冠疫苗及其他生物藥的全球供應能力。
預計該兩座生產工廠將於2021年投入生產,為集團歐洲生產供應鏈提供有力支持。此外,該等交易作為集團"藥明生物提供全球雙廠生產"策略的關鍵一環,可與其現有產能產生強大的協同效應,持續提供高質量和高效的生產服務,賦能全球合作伙伴,造福廣大病患。
Bayer為一間全球企業,其核心競爭力在於醫療保健及營養方面的生命科學領域。該公司通過努力克服全球人口不斷增長及老齡化所帶來的主要挑戰,以其產品及服務造福人類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.